-
Something wrong with this record ?
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
M. Santoni, F. Massari, H. Takeshita, JC. Tapia, M. Dionese, R. Pichler, M. Rizzo, ET. Lam, E. Grande, R. Kemp, J. Molina-Cerrillo, F. Calabrò, D. Tural, Z. Küronya, J. Kucharz, O. Fiala, E. Seront, RM. Kopp, H. Abahssain, J. Kopecky, A....
Language English Country Italy
Document type Journal Article
NLK
Medline Complete (EBSCOhost)
from 2003-05-01 to 1 year ago
Springer Nature OA/Free Journals
from 2001-06-01
- MeSH
- Antineoplastic Agents * therapeutic use MeSH
- Carcinoma, Transitional Cell * drug therapy radiotherapy MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Liver Neoplasms * drug therapy MeSH
- Bone Neoplasms * drug therapy radiotherapy MeSH
- Urinary Bladder Neoplasms * pathology MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The ARON-2 study (NCT05290038) aimed to assess the real-world efficacy of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. This retrospective analysis reports the outcomes of urothelial carcinoma (UC) patients with bone metastases (BM). Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were reviewed from60 institutions in 20 countries. Patients were assessed for Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 881 patients were included; of them, 263 (30%) presented BM. Median follow-up time was 22.7 months. Patients with BM showed both shorter median OS (5.9 months vs 13.1 months, p < 0.001) and PFS (3.5 months, vs 7.3 months, p < 0.001) compared to patients without BM. Patients who received bone targeted agents (BTAs) showed a significantly longer median OS (8.5 months vs 4.6 months, p = 0.003) and PFS (6.1 months vs 3.2 months, p = 0.003), while no survival benefits were observed among patients who received radiation therapy for BM during pembrolizumab treatment compared to those who did not. In multivariate analysis, performance status, concomitant liver metastases, and the lack of use of BTAs were significantly associated with worse OS and PFS. Bone involvement in UC patients treated with pembrolizumab predicts inferior survival. Poor performance status and liver metastases may further worsen outcomes, while the use of BTAs is associated with improved outcomes.
Chair of Oncology Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy
Clinical Oncology Sociedad de Oncología y Hematología del Cesar Valledupar Colombia
Dana Farber Cancer Institute Harvard Medical School Boston MA USA
Department of Medical Oncology Centre Hospitalier de Jolimont Haine Saint Paul La Louvière Belgium
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology King Hussein Cancer Center Amman Jordan
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Oncology San Camillo Forlanini Hospital Rome Italy
Department of Urology Medical University of Innsbruck Anichstrasse 35 6020 Innsbruck Austria
Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan
Division of Medical Oncology A O U Consorziale Policlinico di Bari Bari Italy
Klinik fürUrologie Ratzeburger Allee 160 23538 Lübeck Germany
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Via Albertoni 15 Bologna Italy
Medical Oncology Tawam Hospital Al Ain United Arab Emirates
National Cancer Centre Singapore Singapore Singapore
Oncology Unit Macerata Hospital via Santa Lucia 2 62100 Macerata Italy
Southampton Experimental Cancer Medicine Centre University of Southampton Southampton UK
University of Colorado Anschutz Medical Campus Aurora CO USA
UOC Oncologia A Policlinico Umberto 1 Sapienza University of Rome Rome Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000379
- 003
- CZ-PrNML
- 005
- 20240213093135.0
- 007
- ta
- 008
- 240109s2023 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10238-023-01235-6 $2 doi
- 035 __
- $a (PubMed)37917218
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy
- 245 10
- $a Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study / $c M. Santoni, F. Massari, H. Takeshita, JC. Tapia, M. Dionese, R. Pichler, M. Rizzo, ET. Lam, E. Grande, R. Kemp, J. Molina-Cerrillo, F. Calabrò, D. Tural, Z. Küronya, J. Kucharz, O. Fiala, E. Seront, RM. Kopp, H. Abahssain, J. Kopecky, A. Martignetti, R. Kanesvaran, R. Zakopoulou, J. Ansari, J. Landmesser, V. Mollica, C. Porta, J. Bellmunt, S. Salah, D. Santini
- 520 9_
- $a The ARON-2 study (NCT05290038) aimed to assess the real-world efficacy of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. This retrospective analysis reports the outcomes of urothelial carcinoma (UC) patients with bone metastases (BM). Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were reviewed from60 institutions in 20 countries. Patients were assessed for Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 881 patients were included; of them, 263 (30%) presented BM. Median follow-up time was 22.7 months. Patients with BM showed both shorter median OS (5.9 months vs 13.1 months, p < 0.001) and PFS (3.5 months, vs 7.3 months, p < 0.001) compared to patients without BM. Patients who received bone targeted agents (BTAs) showed a significantly longer median OS (8.5 months vs 4.6 months, p = 0.003) and PFS (6.1 months vs 3.2 months, p = 0.003), while no survival benefits were observed among patients who received radiation therapy for BM during pembrolizumab treatment compared to those who did not. In multivariate analysis, performance status, concomitant liver metastases, and the lack of use of BTAs were significantly associated with worse OS and PFS. Bone involvement in UC patients treated with pembrolizumab predicts inferior survival. Poor performance status and liver metastases may further worsen outcomes, while the use of BTAs is associated with improved outcomes.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z přechodných buněk $x farmakoterapie $x radioterapie $7 D002295
- 650 12
- $a nádory močového měchýře $x patologie $7 D001749
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 12
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 12
- $a nádory kostí $x farmakoterapie $x radioterapie $7 D001859
- 650 12
- $a nádory jater $x farmakoterapie $7 D008113
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy
- 700 1_
- $a Takeshita, Hideki $u Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
- 700 1_
- $a Tapia, Jose Carlos $u Department of Medical Oncology, Institut d'Investigació Biomèdica Sant Pau, Hospital de la Santa Creui Sant Pau, Barcelona, Spain
- 700 1_
- $a Dionese, Michele $u Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV - IRCCS, 35128, Padua, Italy
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
- 700 1_
- $a Rizzo, Mimma $u Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy
- 700 1_
- $a Lam, Elaine T $u University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 700 1_
- $a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
- 700 1_
- $a Kemp, Robert $u Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Calabrò, Fabio $u Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
- 700 1_
- $a Tural, Deniz $u Department of Medical Oncology, Bakirköy Dr.SadiKonuk Training and Research Hospital, Zuhuratbaba District, TevfikSaglam St. No: 11, Bakirkoy, Istanbul, Turkey
- 700 1_
- $a Küronya, Zsófia $u Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Kucharz, Jakub $u Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alejSvobody 76, Pilsen, Czech Republic
- 700 1_
- $a Seront, Emmanuel $u Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, La Louvière, Belgium
- 700 1_
- $a Kopp, Ray Manneh $u Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia
- 700 1_
- $a Abahssain, Halima $u Medicine and Pharmacy Faculty, National Institute of Oncology, Medical Oncology Unit, Mohamed V University, Rabat, Morocco
- 700 1_
- $a Kopecky, Jindrich $u Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Martignetti, Angelo $u Dipartimento oncologico usl sud-est toscana-area senese, Località Campostaggia s.n.c., 53036, Poggibonsi, Italy
- 700 1_
- $a Kanesvaran, Ravindran $u National Cancer Centre Singapore, Singapore, Singapore
- 700 1_
- $a Zakopoulou, Roubini $u 2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Ansari, Jawaher $u Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
- 700 1_
- $a Landmesser, Johannes $u Klinik fürUrologie, Ratzeburger Allee 160, 23538, Lübeck, Germany
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy. veronica.mollica7@gmail.com
- 700 1_
- $a Porta, Camillo $u Chair of Oncology, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
- 700 1_
- $a Bellmunt, Joaquim $u Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Salah, Samer $u Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
- 700 1_
- $a Santini, Daniele $u UOC Oncologia A, Policlinico Umberto I, Sapienza, University of Rome, Rome, Italy
- 773 0_
- $w MED00006222 $t Clinical and experimental medicine $x 1591-9528 $g Roč. 23, č. 8 (2023), s. 5413-5422
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37917218 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093132 $b ABA008
- 999 __
- $a ok $b bmc $g 2049191 $s 1210073
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 23 $c 8 $d 5413-5422 $e 20231102 $i 1591-9528 $m Clinical and experimental medicine $n Clin Exp Med $x MED00006222
- LZP __
- $a Pubmed-20240109
